Endothelial purine content. An alternative model for testing antibiotic solutions for intravenous use.
Vorbach
H
H
Department of Infectious Diseases, University Hospital of Vienna, Austria.
Weigel
G
G
Robibaro
B
B
Reiter
M
M
Hlousek
M
M
Armbruster
C
C
Griesmacher
A
A
Georgopoulos
A
A
Graninger
W
W
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002939:Ciprofloxacin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D016576:Fleroxacin / Q000494:pharmacology; D006801:Humans; D015242:Ofloxacin / Q000494:pharmacology; D012996:Solutions; D013928:Thromboxane A2 / Q000378:metabolism; D014471:Umbilical Veins
D000890:Anti-Infective Agents; D012996:Solutions; D013928:Thromboxane A2; D002939:Ciprofloxacin; D000255:Adenosine Triphosphate; D015242:Ofloxacin; D011464:Epoprostenol; D016576:Fleroxacin